Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
That trial, CedLara, was discontinued in June 2022: a pre-specified interim analysis conducted at roughly half of target enrolment concluded that the number of additional patients required to demonstrate a statistically significant effect was too large to justify continuing
The primary endpoint, median OS was 6.5 months for patients with sorafenib and 4.2 months for patients with placebo (Llovet et al., 2008)
Data processing All data obtained from the four assays with the two systems were processed with software (Progenesis QI 3.0.3.0, Nonlinear Dynamic, Newcastle, UK) for peak picking, alignment, and normalization to produce peak intensities for retention time ( t R ) and mass-to-charge ratio ( m/z ) data pairs
they're foundational
